<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04827758</url>
  </required_header>
  <id_info>
    <org_study_id>GHRMSA 1094</org_study_id>
    <secondary_id>IDRCB 2020-A02364-35</secondary_id>
    <nct_id>NCT04827758</nct_id>
  </id_info>
  <brief_title>Evaluation of a Screening Strategy for Sarcopenia: a Monocentric Prospective Cohort Study (STRAS)</brief_title>
  <acronym>STRAS</acronym>
  <official_title>Evaluation of a Screening Strategy for Sarcopenia: a Monocentric Prospective Cohort Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Groupe Hospitalier de la Region de Mulhouse et Sud Alsace</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Groupe Hospitalier de la Region de Mulhouse et Sud Alsace</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective of this study is to determine the prevalence of sarcopenia in patients&#xD;
      hospitalized in the follow-up care and rehabilitation units of the geriatrics department of&#xD;
      the Mulhouse French hospital.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Secondary objectives&#xD;
&#xD;
        1. To assess the performance of the SARC-F questionnaire to screen for sarcopenia ;&#xD;
&#xD;
        2. To describe the characteristics of sarcopenic patients hospitalized in each follow-up&#xD;
           care and rehabilitation unit (i.e. day hospital, full hospitalization);&#xD;
&#xD;
        3. To identify predictive factors of sarcopenia;&#xD;
&#xD;
        4. To determine, in the subgroup of patients hospitalized in the conventional follow-up&#xD;
           care and rehabilitation unit (i.e. full hospitalization), the evolution of sarcopenia&#xD;
           between admission and discharge of the following variables :&#xD;
&#xD;
             1. muscle strength,&#xD;
&#xD;
             2. muscle mass,&#xD;
&#xD;
             3. functional ability,&#xD;
&#xD;
             4. dependency.&#xD;
&#xD;
      Conduct of research&#xD;
&#xD;
      After receiving the written consent of the study participant, all of the following tests and&#xD;
      questionnaires will be performed :&#xD;
&#xD;
        -  SARC-F questionnaire,&#xD;
&#xD;
        -  measurement of muscle strengh by a grip test,&#xD;
&#xD;
        -  measurement of muscle mass by impedancemetry (ASM/size2),&#xD;
&#xD;
        -  4-meter walking speed test,&#xD;
&#xD;
        -  Timed-Up and Go (TUG) test,&#xD;
&#xD;
        -  ADL (Activities of Daily Living) and IADL (Instrumental Activities of Daily Living)&#xD;
           questionnaires.&#xD;
&#xD;
      For patients in day hospital care, the study will end upon completion of these tests.&#xD;
&#xD;
      For patients hospitalized in the conventional follow-up care and rehabilitation unit (i.e.&#xD;
      full hospitalization), a follow-up visit will be scheduled within 72 hours prior to the&#xD;
      patient's discharge from the service, or at 3 months of hospitalization. The following tests&#xD;
      and questionnaires will be performed during this visit:&#xD;
&#xD;
        -  measurement of muscle strengh by a grip test,&#xD;
&#xD;
        -  measurement of muscle mass by impedancemetry,&#xD;
&#xD;
        -  4-meter walking speed test,&#xD;
&#xD;
        -  Timed Up and Go (TUG) test,&#xD;
&#xD;
        -  ADL and IADL questionnaires.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 22, 2021</start_date>
  <completion_date type="Anticipated">September 2021</completion_date>
  <primary_completion_date type="Anticipated">September 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients with sarcopenia</measure>
    <time_frame>Enrollment</time_frame>
    <description>The diagnosis of sarcopenia will be established according to the 2018 criteria of the European Working Group On Sarcopenia in Older People (EWGSOP2) based on the evaluation of muscle strength and muscle mass. Sarcopenia will be defined by an abnormal value measured by a grip test and confirmed by an abnormal value of the ASM/size2 ratio measured by impedancemetry.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Sensitivity, specificity, positive and negative predictive value of the SARC-F questionnaire</measure>
    <time_frame>Enrollment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Characteristics of sarcopenic patients hospitalized in each follow-up care and rehabilitation unit (i.e. day hospital, full hospitalization)</measure>
    <time_frame>Enrollment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Muscle strength</measure>
    <time_frame>Hospital discharge assessed up to 3 months</time_frame>
    <description>In the subgroup of patients hospitalized in the conventional follow-up care and rehabilitation unit (i.e. full hospitalization), the evolution of muscle strength between admission and discharge will be assessed by a grip test. For patients hospitalized for more than 3 months, the grip test will be performed at 3 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Muscle mass</measure>
    <time_frame>Hospital discharge assessed up to 3 months</time_frame>
    <description>In the subgroup of patients hospitalized in the conventional follow-up care and rehabilitation unit (i.e. full hospitalization), the evolution of muscle mass between admission and discharge will be assessed by the measurement of the ASM/size2 (impedancemetry) ratio. For patients hospitalized for more than 3 months, the measurement of muscle mass will be performed at 3 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>4-meter walking speed test</measure>
    <time_frame>Hospital discharge assessed up to 3 months</time_frame>
    <description>In the subgroup of patients hospitalized in the conventional follow-up care and rehabilitation unit (i.e. full hospitalization), the evolution of the value of the 4-meter walking speed test between admission and discharge will be assessed. For patients hospitalized for more than 3 months, the 4-meter walking speed test will be performed at 3 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Timed-Up and Go test (TUG)</measure>
    <time_frame>Hospital discharge assessed up to 3 months</time_frame>
    <description>In the subgroup of patients hospitalized in the conventional follow-up care and rehabilitation unit (i.e. full hospitalization), the evolution of the value of the TUG test between admission and discharge will be assessed. For patients hospitalized for more than 3 months, the TUG test will be performed at 3 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ADL (Activities of Daily Living) questionnaire</measure>
    <time_frame>Hospital discharge assessed up to 3 months</time_frame>
    <description>In the subgroup of patients hospitalized in the conventional follow-up care and rehabilitation unit (i.e. full hospitalization), the ADL questionnaire will also be performed at hospital discharge, or at 3 months for patients hospitalized for more than 3 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IADL (Instrumental Activities of Daily Living) questionnaire</measure>
    <time_frame>Hospital discharge assessed up to 3 months</time_frame>
    <description>In the subgroup of patients hospitalized in the conventional follow-up care and rehabilitation unit (i.e. full hospitalization), the IADL questionnaire will also be performed at hospital discharge, or at 3 months for patients hospitalized for more than 3 months.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Sarcopenia</condition>
  <arm_group>
    <arm_group_label>Patients hospitalized in the follow-up care and rehabilitation units</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Screening and diagnostic tests for sarcopenia</intervention_name>
    <description>All of the following tests and questionnaires will be performed :&#xD;
SARC-F questionnaire,&#xD;
measurement of muscle strengh by a grip test,&#xD;
measurement of muscle mass by impedancemetry (ASM/size2),&#xD;
4-meter walking speed test,&#xD;
Timed-Up and Go (TUG) test,&#xD;
ADL (Activities of Daily Living) and IADL (Instrumental Activities of Daily Living) questionnaires.</description>
    <arm_group_label>Patients hospitalized in the follow-up care and rehabilitation units</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient 60 years of age or older&#xD;
&#xD;
          -  Patients hospitalized in the follow-up care and rehabilitation units (i.e. day&#xD;
             hospital, full hospitalization) of the geriatrics department of the Mulhouse French&#xD;
             hospital&#xD;
&#xD;
          -  Patient who gave consent to participate in the study&#xD;
&#xD;
          -  Affiliated or beneficiary of a social security scheme&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient admitted for palliative care&#xD;
&#xD;
          -  Bedridden patient&#xD;
&#xD;
          -  Patient with major neurocognitive disorders preventing the tests from being performed,&#xD;
             or any other medical condition preventing the diagnostic tests from being performed&#xD;
&#xD;
          -  Patient under legal protection&#xD;
&#xD;
          -  Patient with an unstable psychiatric disorder&#xD;
&#xD;
          -  Patient under guardianship or curatorship&#xD;
&#xD;
          -  Patient already included in the study during a previous hospitalization&#xD;
&#xD;
        Secondary exclusion criteria :&#xD;
&#xD;
        - For patients hospitalized in the conventional follow-up care and rehabilitation unit&#xD;
        (i.e. full hospitalization), diagnostic tests for sarcopenia not performed within 7 days of&#xD;
        admission.&#xD;
&#xD;
        Patients excluded secondarily will not be replaced.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xavier SIRLIN, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Groupe Hospitalier de la Region de Mulhouse et Sud Alsace</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xavier SIRLIN, MD</last_name>
    <phone>+33389646008</phone>
    <email>sirlinx@ghrmsa.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>GHRMSA - HÃ´pital Emile MULLER</name>
      <address>
        <city>Mulhouse</city>
        <zip>68100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xavier SIRLIN, MD</last_name>
    </contact>
    <investigator>
      <last_name>Anna DERAJINSKI, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Eleonore DE GUIO, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>March 24, 2021</study_first_submitted>
  <study_first_submitted_qc>March 30, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 1, 2021</study_first_posted>
  <last_update_submitted>July 7, 2021</last_update_submitted>
  <last_update_submitted_qc>July 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>sarcopenia</keyword>
  <keyword>muscle strength</keyword>
  <keyword>muscle mass</keyword>
  <keyword>older people</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcopenia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

